BRAF and neoplasm: Of note, Braf-mutated or Kras-mutated xenograft tumours that recurred following the treatment with the vemurafenib-based triple combination, tumor xenografts resulted very sensitive to the trametinib-based combination therapy, as shown by the massive tumour regression and lack of regrowth even 6 weeks after treatment suspension (figure 4E).